The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers

Human Vaccines

Volumn 2, Issue 4, 2006, Pages 167-173

  Durbin, Anna P ^a   McArthur, Julie ^a   Marron, Jennifer A ^a   Blaney Jr , Joseph E ^b   Thumar, Bhavin ^a   Wanionek, Kim ^a   Murphy, Brian R ^b   Whitehead, Stephen S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Live attenuated dengue serotype 1 vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT DEN1 DELTA30 VACCINE; RECOMBINANT DEN4 DELTA30 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHADENOPATHY; MACULOPAPULAR RASH; MALAISE; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PETECHIA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; THROMBOCYTOPATHY; VIRAL PHARYNGITIS; VIREMIA;

EID: 33748847886     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2.4.2944     Document Type: Article

References (42)

1. Lindenback B, Rice C. Flaviviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, eds. Fields Virology. Fourth ed. Vol. 1. Baltimore: Lippincott Williams & Wilkins, 2001:963-1041.
2. Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, eds. Fields Virology. Fourth ed. Vol. 1. Baltimore: Lippincott Williams and Wilkins, 2001:1043-125.
3. WHO. Dengue and dengue haemorrhagic fever. WHO Fact Sheet: WHO, 2002.
4. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: WHO, 1997.
5. Sabin A. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
6. Burke DS, Nisalak A, Johnson DE and Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172-80.
7. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 1945; 101:640-42.
8. Schlesinger RW, Gordon I, Frankel JW, Winter JW, Patterson PR and Dorrance WR. Clinical and serologic response of man to immunization with attnuated dengue and yellow fever viruses. J Immunol 1956; 77:352-64.
9. Wisseman CJ, Sweet B, Rosenzweig E and Eylar O. Attenuated living type 1 dengue vaccines. Am J Trop Med Hyg 1963; 12:620-3.
10. Bellanti JA, Bourke RTA, Rosenzweig EC and Eylar OR. Report of dengue vaccine trial in the Caribbean, 1963: a collaborative study. Bull World Health Organ 1966; 35:93.
11. Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL and Hoke CH. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 1994; 170:1448-55.
12. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL and Sun W. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
13. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF and Hoke CH, Jr. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179-88.
14. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH, Jr. and Innis BL. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:24-31.
15. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18:44-7.
16. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J and Saluzzo JF. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2005.
17. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR and Whitehead SS. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001; 65:405-13.
18. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE, Jr., Thumar B, Murphy BR and Karron RA. rDEN4 Delta 30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers. J Infect Dis 2005; 191:710-8.
19. Brinton MA, Fernandez AV and Dispoto JH. The 3′-nucleotides of flavivirus genomic RNA form a conserved secondary structure. Virology 1986; 153:113-21.
20. Hahn CS, Hahn YS, Rice CM, Lee E, Dalgarno L, Strauss EG and Strauss JH. Conserved elements in the 3′ untranslated region of flavivirus RNAs and potential cyclization sequences. J Mol Biol 1987; 198:33-41.
21. Rauscher S, Flamm C, Mandl CW, Heinz FX and Stadler PF. Secondary structure of the 3′-noncoding region of flavivirus genomes: comparative analysis of base pairing probabilities. Rna 1997; 3:779-91.
22. Proutski V, Gould EA and Holmes EC. Secondary structure of the 3′ untranslated region of flaviviruses: similarities and differences. Nucleic Acids Res 1997; 25:1194-202.
23. Whitehead SS, Falgout B, Hanley KA, Blaney Jr JE, Jr., Markoff L and Murphy BR. A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys. J Virol 2003; 77:1653-7.
24. Blaney JE, Jr., Matro JM, Murphy BR and Whitehead SS. Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys. J Virol 2005; 79:5516-28.
25. Murgue B, Roche C, Chungue E and Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000; 60:432-8.
26. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA and Nisalak A. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
27. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, Chansiriwongs W, Vaughn DW, Nisalak A, Ennis FA and Rothman AL. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213-21.
28. Halstead SB. Etiologies of the experimental dengues of Siler and Simmons. Am J Trop Med Hyg 1974; 23:974-82.
29. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF and Bhamarapravati N. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23:99-109.
30. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF and Bhamarapravati N. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66:264-72.
31. Kanesa-thasan N, Hernandez L, Lyons A, Putnak R, Sun W, McKinney D and Vaughn DW. A phase I study of the WRAIR tetravalent live attenuated dengue vaccine in flavivirus-immune adult volunteers. In: 5th Annual Conference on Vaccine Research. Baltimore MD, 2002.
32. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J and Saluzzo JF. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006; 24:1238-41.
33. Men R, Bray M, Clark D, Chanock RM and Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70:3930-7.
34. Zeng L, Falgout B and Markoff L. Identification of specific nucleotide sequences within the conserved 3′-SL in the dengue type 2 virus genome required for replication. J Virol 1998; 72:7510-22.
35. Markoff L, Pang X, Houng Hs HS, Falgout B, Olsen R, Jones E and Polo S. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 2002; 76:3318-28.
36. Alvarez DE, De Lella Ezcurra AL, Fucito S and Gamarnik AV. Role of RNA structures present at the 3′UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 2005; 339:200-12.
37. Proutski V, Gritsun TS, Guld EA and Holmes EC. Biological consequences of deletions within the 3′-untranslated region of flaviviruses may be due to rearrangements of RNA secondary structure. Virus Res 1999; 64:107-23.
38. Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP and Murphy BR. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg 2001; 65:414-9.
39. Blaney JE, Jr., Hanson CT, Firestone CY, Hanley KA, Murphy BR and Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004; 71:811-21.
40. Blaney JE, Jr., Hanson CT, Hanley KA, Murphy BR and Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis 2004; 4:39.
41. Whitehead SS, Hanley KA, Blaney JE, Jr., Gilmore LE, Elkins WR and Murphy BR. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003; 21:4307-16.
42. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004; 363:2073-5.